This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (13)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jack Hirsh, MD

Arch Intern Med. 1991;151(10):1921-1922.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The popularity of warfarin, a drug that has been in clinical use for approximately 50 years, has waxed and waned and is currently on the rise. The recent interest in clinical use has been stimulated by the observation that less intense warfarin regimens are as effective as, but produce much less bleeding than, the high-intensity regimens that were standard in North America in the past. Thus, results of randomized trials have demonstrated that low-intensity regimens are as effective as, but much safer than, high-intensity regimens for the treatment of venous thrombosis and for the prevention of systemic embolism in patients with tissue heart valves and, more recently, in patients with mechanical heart valves^1-3 (Table). These findings provided the impetus for clinical trials assessing the relative risks and benefits of low-intensity warfarin in patients with nonvalvular atrial fibrillation.^4,5 The results have been impressive—a greater than 60% risk reduction in . . . [Full Text PDF of this Article]

Author Affiliations
Hamilton Civic Hospitals Research Centre 711 Concession St Hamilton, Ontario L8V 1C3 Canada

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?